Regulatory Decision-Making Meets the Real World

Friends publishes commentary in Science Translational Medicine and Whitepaper Report on patient-centered drug development. Links below:

AAAS' Science Translational Medicine

Friends Whitepaper - Enhancing Use of Patient-Centered Data in Regulatory Decision Making


19th Annual Cancer Leadership Awards Reception

Friends Honors Rep. Fred Upton, Rep. Diana DeGette, and President Marlene Malek as Dr. Francis Collins sings, "If Not Now, Tell Me When"

Read More

Ellen Sigal Op-Ed in The Hill on Updating FDA Structure

Ellen Sigal Calls for updated FDA structure for 21st Century science and patient needs

Read More

2014 Conference on Clinical Cancer Research

Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.

Read More

Accelerating Science and Technology

Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way possible.

Read More

New collaborative clinical trial launches

Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP

Read More

Breakthrough Therapies In Action

The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.

Read More

Breakthrough Designations

View More

Avelumab - (Merck KGaA/Pfizer)

for the treatment of metastatic Merkel cell carcinoma (MCC) following progression on at least one prior chemotherapy regimen


SD-809 (deutetrabenazine) - (Teva)

for the treatment of patients with moderate to severe tardive dyskinesia


Pembrolizumab - (Merck)

for the treatment of Microsatellite Instability-High (MSI-H) metastatic colorectal cancer (mCRC)